Cerenovus enters flow diverter market with hopes to improve patient care

Medical device company Cerenovus has announced it has received European CE mark approval for a device to be used in the treatment of patients suffering from intracranial aneurysms.

The company’s Bravo Flow Diverter diverts blood flow from an aneurysm to promote healing, reducing the risk of rupture, one of the main causes of hemorrhagic stroke.

The Bravo Flow Diverter marks Cerenovus’ first entry into the flow diverter category and adds to its portfolio of devices used in endovascular treatment of hemorrhagic and ischemic stroke. The company hopes that the device helps to improve clinicians ease of use, improve cost effectiveness and reduce the length of procedures.

Professor Patrick Brouwer senior consultant Neurointerventionalist at Karolinska University Hospital and Evaluator for Bravo Flow Diverter, said: “Flow diverters are now widely used and for many, have become the go to option for the treatment of complex aneurysms. I believe the design of the Bravo Flow Diverter, particularly the proximal and distal expansion rings, provides a fresh approach to treat aneurysms.”

“The Bravo Flow Diverter builds on our legacy of providing meaningful innovation to enable patients to live a life free from the burden of stroke” said Daniella Cramp, Cerenovus Worldwide President. “Our entry into the flow diverter market demonstrates our commitment to push the boundaries of stroke treatment and marks a key step towards changing the trajectory of stroke”.